[1]毛晓楠,卢再鸣,郭启勇.门静脉支架联合125I粒子条植入治疗门脉癌栓12例[J].介入放射学杂志,2016,(12):1058-1064.
 MAO Xiao- nan,LU Zai- ming,GUO Qi- yong.Portal vein stenting combined with 125I strand implantation for the treatment of portal vein tumor thrombus: initial results in 12 patients[J].journal interventional radiology,2016,(12):1058-1064.
点击复制

门静脉支架联合125I粒子条植入治疗门脉癌栓12例 ()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2016年12期
页码:
1058-1064
栏目:
肿瘤介入
出版日期:
2016-12-25

文章信息/Info

Title:
Portal vein stenting combined with 125I strand implantation for the treatment of portal vein tumor thrombus: initial results in 12 patients
作者:
毛晓楠 卢再鸣 郭启勇
Author(s):
MAO Xiao- nan LU Zai- ming GUO Qi- yong
Department of Radiology, Affiliated Shengjing Hospital of China Medical University, Shenyang, Liaoning Province 110022, China
关键词:
【关键词】 门静脉 癌栓 支架 125I
文献标志码:
A
摘要:
【摘要】 目的 介绍用门静脉支架联合125I粒子条对合并门脉癌栓的肝癌患者的综合治疗方法。方法 汇集自2014年以来中国医科大学附属盛京医院放射科收治的肝癌合并门脉癌栓的患者12例,分析其临床、影像、实验室检查资料,完成经皮经肝门静脉穿刺及支架联合125I粒子条植入术,统计手术的可行性、安全性及并发症,讨论支架的通畅情况及患者的生存情况。结果 手术成功12例(100%),2例支架未开通,其中1例并发穿刺点出血,1例并发呕血。10例患者接受随访,平均随访时间8.0个月(2~15个月),平均生存时间8.0个月(2~15个月)。术后3、6和9个月及1年生存率分别为7/9、7/9、5/8和3/6。门脉支架平均通畅时间7.5个月(0~15个月)。术后3、6和9个月、1年门静脉通畅率分别为7/9、6/9、5/8和3/6。随访期内共8例患者行后续TACE治疗,共行TACE 18例次,术后肝功能稳定。结论 门静脉支架联合125I粒子条植入可以降低癌栓分级、维持支架通畅、保证门脉供血、扩大TACE适应证,对合并门脉癌栓的肝细胞癌患者具有较大的综合治疗价值。

参考文献/References:

[1] Ikai I, Hatano E, Hasegawa S, et al. Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein[J]. J Am Coll Surg, 2006, 202: 431- 438.
[2] Hata M, Tokuuye K, Sugahara S, et al. Proton irradiation in a single fraction for hepatocellular carcinoma patients with uncontrollable ascites. Technical considerations and results[J]. Strahlenther Onkol, 2007, 183: 411- 416.
[3] Tsukamoto T, Hirohashi K, Kubo S, et al. Percutaneous transhepatic metallic stent placement for malignant portal vein stenosis[J]. Hepatogastroenterology, 2003, 50: 453- 455.
[4] Abdel- Wahab M, El- Ghawalby N, Mostafa M, et al. Epidemiology of hepatocellular carcinoma in lower Egypt, Mansoura Gastroent- erology Center[J]. Hepatogastroenterology, 2007, 54: 157- 162.
[5] Takizawa D, Kakizaki S, Sohara N, et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical charac- teristics, prognosis, and patient survival analysis[J]. Dig Dis Sci, 2007, 52: 3290- 3295.
[6] Yeung YP, Lo CM, Liu CL, et al. Natural history of untreated nonsurgical hepatocellular carcinoma[J]. Am J Gastroenterol, 2005, 100: 1995- 2004.
[7] Kadouchi K, Higuchi K, Shiba M, et al. What are the risk factors for aggravation of esophageal varices in patients with hepatocellular carcinoma?[J]. J Gastroenterol Hepatol, 2007, 22: 240- 246.
[8 ] Zhang XB, Wang JH, Yan ZP, et al. Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3- dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization[J]. Cancer, 2009, 115: 1245- 1252.
[9] 张 磊, 陆骊工, 李 勇, 等. 门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J]. 介入放射学杂志, 2011, 20: 968- 973.
[10] Yamakado K, Nakatsuka A, Tanaka N, et al. Portal venous stent placement in patients with pancreatic and biliary neoplasms invading portal veins and causing portal hypertension: initial experience[J]. Radiology, 2001, 220: 150- 156.
[11] 刘清欣, 颜志平, 李 说, 等. 125I粒子条联合门静脉支架及化疗栓塞治疗原发性肝癌合并门静脉癌栓[J]. 介入放射学杂志, 2009, 18: 593- 595.
[12] 罗剑钧, 颜志平, 王建华, 等. 腔内植入125I粒子条及支架联合经动脉化疗栓塞治疗原发性肝癌合并门脉主干癌栓的疗效[J]. 中华肿瘤杂志, 2011, 33: 535- 539.
[13] 吴林霖, 罗剑钧, 颜志平, 等. 门脉支架及TACE联合或未联合血管内植入125I粒子条治疗肝癌合并门脉主干癌栓(MPVTT)的随机对照研究[J]. 复旦学报?医学版, 2013, 40: 354- 359.
[14] 张子寒, 罗剑钧, 颜志平, 等. 血管内近程放疗联合支架植入及经动脉化疗栓塞治疗肝细胞肝癌合并门脉主干癌栓[J]. 复旦学报?医学版, 2016, 43: 1- 8.
[15] 吴林霖, 颜志平, 张 雯, 等. 经动脉灌注化疗联合125I粒子条治疗原发性肝癌合并门脉癌栓的疗效分析[J]. 介入放射学杂志, 2015, 24: 776- 780.

相似文献/References:

[1]程洁敏,王建华.喜树碱微球化疗栓塞治疗原发性肝癌10例报告[J].介入放射学杂志,1993,(01):47.
[2]张 雯,颜志平,罗剑钧,等.成功抢救下腔静脉癌栓支架植入后肺栓塞一例[J].介入放射学杂志,2011,(02):167.
 ZHANG Wen,YAN Zhi-ping,LUO Jian-jun,et al.Successful rescue of pulmonary embolism in HCC patient after stent implantation[J].journal interventional radiology,2011,(12):167.
[3]涂文辉,罗剑钧,刘清欣,等.原发性肝癌伴门静脉主干癌栓患者存活超5年1例并文献复习[J].介入放射学杂志,2015,(12):1101.
 TU Wen- hui,LUO Jian- jun,LIU Qing- xin,et al.Primary hepatocellular carcinoma associated with portal vein tumor thrombus: report of one case with survival over 5 years and review of literature [J].journal interventional radiology,2015,(12):1101.
[4]武 贝,高 杨,席 玮,等.兔VX2门静脉癌栓模型构建[J].介入放射学杂志,2016,(03):239.
 WU Bei,GAO Yang,XI Wei,et al.The establishment of VX2 portal vein tumor thrombus model in experimental rabbits[J].journal interventional radiology,2016,(12):239.
[5]谢伶俐,梁 斌,苏扬波,等.介入栓塞治疗胃十二指肠动脉-门静脉瘘1例 [J].介入放射学杂志,2017,(08):687.
 XIE Lingli,LIANG Bin,SU Yangbo,et al.Successful interventional embolization treatment of gastroduodenal arterioportal fistula: report of one case[J].journal interventional radiology,2017,(12):687.
[6]陆 孜,潘文秋,赵 卫,等.罕见性肝外弥漫性动脉- 门静脉瘘治疗失败 1例[J].介入放射学杂志,2020,29(12):1284.
 LU Zi,PAN Wenqiu,ZHAO Wei,et al.Treatment failure of rare extrahepatic diffuse arterioportal fistula: report of one case[J].journal interventional radiology,2020,29(12):1284.
[7]杨胜利,顾俊鹏,鲍应军,等.粒子支架植入治疗Ⅳ型门脉癌栓1例 [J].介入放射学杂志,2020,29(11):1174.
 YANG Shengli,GU Junpeng,BAO Yingjun,et al.125I seed stent implantation for type Ⅳ portal vein tumor thrombus: report of one case[J].journal interventional radiology,2020,29(12):1174.

备注/Memo

备注/Memo:
(收稿日期:2016-05-28)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2016-12-15